MarketGrader Europe 100 Index


Five Largest Companies
Symbol Name Grade Market Cap Country
ASML.NL ASML Holding NV 70.3 ¤364,880 NL
SAP.DE SAP SE 56.5 ¤310,553 DE
AZN.GB AstraZeneca PLC 65.8 ¤264,186 GB
NOVO.B.DK Novo Nordisk A/S Class B 70.7 ¤259,309 DK
NOVN.CH Novartis AG 60.1 ¤247,619 CH

Five Smallest Companies
Symbol Name Grade Market Cap Country
ENX.FR Euronext NV 57.6 ¤14,669 NL
SN.GB Smith & Nephew plc 59.8 ¤14,969 GB
BIM.FR bioMerieux SA 50.2 ¤15,677 FR
SOON.CH Sonova Holding AG 55.5 ¤16,126 CH
CCH.GB Coca-Cola HBC AG 63.4 ¤16,342 CH

Companies with Most Selections Among Current Components
Symbol Name Grade Times* Country
ASML.NL ASML Holding NV 70.3 33 NL
ACN Accenture Plc Class A 60.1 32 IE
DNB.NO DNB Bank ASA 66.3 29 NO
ALV.DE Allianz SE 54.8 28 DE
LR.FR Legrand SA 61.1 28 FR
NOVO.B.DK Novo Nordisk A/S Class B 70.7 28 DK
ASSA.B.SE ASSA ABLOY AB Class B 54.1 27 SE
TEL TE Connectivity plc 55.3 26 IE
ETN Eaton Corp. Plc 55.9 25 IE
SAND.SE Sandvik AB 53.1 24 SE
*Number of times selected at Index semi-annual reconstitutions since inception date.
Index Bio
Average Market Cap ¤69,938
Median Market Cap ¤40,862
Avg. 3 Mo. Dollar Vol. ¤154,405,548
Avg. 3 Mo. Trading Vol. 5,480,441
Last Rebalance Date 09/22/2025
Companies Replaced 49
Biggest Sector Increase Health Care
Biggest Sector Decrease Utilities

Fundamental Attributes
Trailing P/E Ratio (12 Mo.) 17.6
Forward P/E Ratio (12 Mo.) 14.9
Price/Book Ratio 3.3
Avg. Revenue Chg. - 3 Yr 31.4%
Avg. Op. Income Chg. - 3 Yr. 50.3%
Avg. EPS Growth - 3 Yr. 15.6%
Avg. EPS Growth - 1 Yr. 19.7%
Avg. Operating Margin 18.7%
Avg. LT Debt to Total Capital 40.8%
Avg. Return on Equity 16.4%
Dividend Yield 2%
Index Average Grade
Europe 100 Index 58.71
Country Breakdown
United Kingdom 22.0%
Germany 14.0%
Switzerland 10.0%
Ireland 10.0%
Netherlands 9.0%
Sweden 7.0%
France 7.0%
Italy 6.0%
Spain 5.0%
Denmark 2.0%
Belgium 2.0%
Norway 2.0%
Luxembourg 1.0%
Hong Kong 1.0%
Austria 1.0%
Finland 1.0%
For more information on this index please contact us

Get Access to the World's Smartest Global Research Platform

Don't wait another day to make better informed, higher-returning investments.

TRY IT FOR FREE